Senti Biosciences Holdings, Inc. filed a Form 8-K with the SEC on November 18, 2026, disclosing that it effected a 1-for-33 reverse stock split of its common stock, effective as of 5:00 p.m. Eastern Time that same day.

Key Highlights

  • Split ratio: Every 33 shares of common stock were automatically reclassified into one new share of common stock at a 1-for-33 ratio.
  • Effective time: The reverse stock split became effective at 5:00 p.m. Eastern Time on November 18, 2026.
  • Board approval date: The Board of Directors approved the 1-for-33 ratio on October 26, 2026, following stockholder approval at the 2026 Annual Meeting.
  • Stockholder authorization: Stockholders approved a split ratio ranging from 1-for-20 to 1-for-50 at the Annual Meeting held on October 8, 2026, reconvened October 15, 2026.
  • Fractional shares: No fractional shares will be issued; stockholders entitled to a fractional share will have it rounded up to the nearest whole share.
  • No change to authorized shares or par value: The reverse stock split did not affect the number of authorized shares of common stock or the $0.0001 par value per share.
  • New CUSIP: The new CUSIP number for the common stock following the reverse stock split is 816944201.

Senti Biosciences Implements 1-for-33 Reverse Split, Trading Adjusts November 19

According to the filing, Senti Biosciences Holdings, Inc. (NASDAQ:SNTI) filed an amendment to its Amended and Restated Certificate of Incorporation on November 18, 2026, to carry out the reverse stock split. The company disclosed that every 33 issued and outstanding shares of common stock were automatically reclassified into one validly issued, fully paid, and non-assessable new share of common stock, without any action required on the part of stockholders.

The filing states that the Board of Directors selected the 1-for-33 ratio on October 26, 2026, drawing on authority granted by stockholders at the 2026 Annual Meeting. At that meeting, held on October 8, 2026, and reconvened on October 15, 2026, stockholders approved a certificate of amendment permitting a ratio of any whole number between 1-for-20 and 1-for-50, subject to the Board's discretion and its authority to abandon the amendment. The reverse stock split was described in detail under "Proposal 5" in the company's definitive proxy statement filed with the SEC on September 24, 2026.

The company disclosed that proportionate adjustments will be made to the exercise prices and number of shares underlying outstanding equity awards, as applicable, and to certain existing agreements. The filing notes that trading of the common stock on The Nasdaq Capital Market is expected to commence on a split-adjusted basis when the market opens on November 19, 2026, under the existing trading symbol "SNTI." The filing also contains forward-looking statements, which the company characterizes as subject to risks and uncertainties and cautions investors not to place undue reliance on them.

What Was Disclosed

Senti Biosciences Holdings, Inc. reported the filing of a certificate of amendment to effect a 1-for-33 reverse stock split of its common stock, effective November 18, 2026, with split-adjusted trading on The Nasdaq Capital Market expected to begin November 19, 2026, under the symbol "SNTI."